Clinical characteristics, treatment patterns, and overall survival in adolescent and young adult versus adult patients with non-M3 acute myeloid leukemia in Palestine: a retrospective single-center cohort study

Blood is a living river that carries oxygen and nutrients to every part of the body, but sometimes the cells that make up this river go wrong. In a condition called acute myeloid leukemia, the bone marrow—the soft, spongy tissue inside our bones that normally acts as a factory for healthy blood cells—begins to produce too many immature, defective cells. These immature cells crowd out the healthy ones, leaving the body unable to fight infections or carry oxygen properly. While this disease is most common in older adults, it also strikes adolescents and young adults, a group roughly between the ages of fifteen and thirty-nine. Doctors have long wondered if these younger patients, who often have stronger bodies and different life priorities, respond to treatment differently than older adults. They also want to know if the specific way the disease behaves or the way it is treated changes the length of a patient's life. Understanding these differences is crucial because it helps doctors decide whether to treat a twenty-year-old the same way they treat a sixty-year-old, or if the approach needs to be tailored to the patient's age and strength.

In a recent study conducted at a single hospital in Nablus, Palestine, researchers set out to examine these questions using real-world data from their own patients. They looked back at the medical records of 158 people diagnosed with a specific type of this blood cancer, excluding a rare variant known as M3, between May 2014 and December 2023. The team split these patients into two groups: the younger group, aged fifteen to thirty-nine, and the older group, aged forty and above. By comparing how these two groups looked when they first arrived at the hospital, what treatments they received, and how long they lived after their diagnosis, the researchers hoped to paint a clear picture of how this disease plays out in their local community.

When the researchers examined the patients' condition at the moment of diagnosis, they found that the younger group was generally in better physical shape. Almost all of the adolescents and young adults were able to carry out their normal daily activities without limitation, whereas a significant portion of the older adults already had some difficulty with daily tasks. The blood tests also told a story of difference. The younger patients had lower levels of waste products in their blood, suggesting their kidneys were working more efficiently, but they had higher levels of certain liver enzymes and a greater number of cancer cells in their bone marrow. Despite these biological differences, the two groups were similar in other ways; for instance, the number of men and women was nearly the same in both groups, and the rate of smoking was comparable.

The treatment paths taken by these two groups diverged sharply. The younger patients almost universally received a powerful, intensive combination of chemotherapy drugs designed to aggressively wipe out the cancer cells. In contrast, the older patients were treated with a wider variety of approaches; while many also received the intensive drugs, a large number were given a different medication that works more gently, often chosen because it is better tolerated by older bodies. The study also looked at whether patients received a bone marrow transplant, a procedure where a patient's diseased marrow is replaced with healthy marrow from a donor. While the younger group underwent this procedure more often than the older group, the difference was not large enough to be considered statistically significant, meaning it could have happened by chance.

Perhaps the most surprising finding concerned how long the patients lived. In medicine, it is often assumed that younger patients with stronger bodies will survive longer than older patients, especially when they receive more aggressive treatment. However, in this specific group of patients, the researchers found no such advantage. When they tracked the time from diagnosis until death, the median survival time for the younger group was about twenty-seven months, while the older group survived for about thirty-six months. Although the older group lived slightly longer on average, the difference was so small that it was not statistically meaningful. The survival curves for both groups were essentially the same, suggesting that in this particular setting, age alone did not determine who lived longer.

The researchers were careful to explain why these results might look this way. They noted that their study was limited because it focused on a single hospital and did not have access to detailed genetic information about the cancer cells, which is often the most important factor in predicting outcomes. They also pointed out that the data on whether patients went into remission—a state where the cancer is no longer detectable—was incomplete for many patients. Because of these gaps, the study cannot prove that age has no effect on survival, nor can it prove that the treatments worked equally well for everyone. Instead, the findings serve as a detailed description of what happened in this specific community. The study highlights that while younger patients are fitter and receive more intense treatment, this did not translate into a clear survival advantage over older patients in this dataset.

Ultimately, this work adds a valuable piece to the puzzle of understanding leukemia in the Middle East. It shows that in this region, the journey of a young patient with this disease looks different from that of an older patient in terms of their physical condition at the start and the medicines they receive. Yet, the final outcome in terms of survival remains a complex picture that is not simply solved by age. The authors conclude that to truly understand these differences, future studies will need to involve many hospitals working together, include more detailed genetic testing, and track patient responses more completely. Until then, this report stands as a clear, honest look at the reality of treating acute myeloid leukemia in Palestine, reminding us that while age shapes the path, it does not always dictate the destination.